Paul Tudor Jones Syndax Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 53,056 shares of SNDX stock, worth $710,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,056
Previous 66,988
20.8%
Holding current value
$710,419
Previous $823,000
39.61%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SNDX
# of Institutions
252Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$114 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$106 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$77.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$67.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$54.4 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $757M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...